Why the study?
Humanization of antibodies to develop novel therapeutic agents with low immunogenicity remains an important scientific challenge.
Population
Transient CHO cells expressing humanized hB16 and chimeric chB16 antibodies
Comparison
Humanized antibody hB16 vs murine mAb B16 and chimeric antibody chB16
Design
Preclinical laboratory study
Key result
Humanized antibody hB16 possesses the same properties as murine mAb B16 in binding and neutralizing human interferon-beta.
Authors
Loading...
Offers candidate for IFN-beta/ErbB2 immune complex; leaves open clinical translation pending human trials.
The successful humanization of murine antibody B16 provides a potential component for a therapeutic immune complex targeting interferon-beta and the ErbB2 receptor.
Рыбченко et al. (2020) studied this question. Humanized antibody hB16 vs. Murine mAb B16 was evaluated on Antibody properties (binding and neutralizing human interferon-beta). Humanized antibody hB16 possesses the same properties as murine mAb B16 in binding and neutralizing human interferon-beta.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: